Femasys (NASDAQ:FEMY) Stock Price Down 2.8% – What’s Next?

Femasys Inc. (NASDAQ:FEMY)’s stock price was down 2.8% during trading on Monday . The stock traded as low as $1.04 and last traded at $1.05. Approximately 60,751 shares were traded during mid-day trading, a decline of 20% from the average daily volume of 75,964 shares. The stock had previously closed at $1.08.

Wall Street Analysts Forecast Growth

A number of analysts have recently issued reports on the stock. HC Wainwright restated a “buy” rating and set a $12.00 target price on shares of Femasys in a research note on Tuesday, December 3rd. Chardan Capital reduced their price target on Femasys from $10.00 to $8.00 and set a “buy” rating for the company in a research note on Wednesday, November 13th.

Femasys Trading Down 2.8 %

The company has a current ratio of 3.94, a quick ratio of 3.26 and a debt-to-equity ratio of 0.86. The stock has a market capitalization of $24.04 million, a P/E ratio of -1.30 and a beta of -2.82. The business has a 50-day moving average price of $1.09 and a two-hundred day moving average price of $1.12.

Femasys (NASDAQ:FEMY) last issued its earnings results on Tuesday, November 12th. The company reported ($0.24) EPS for the quarter, missing the consensus estimate of ($0.20) by ($0.04). Femasys had a negative net margin of 1,435.77% and a negative return on equity of 141.49%. The firm had revenue of $0.55 million during the quarter, compared to analyst estimates of $0.40 million. On average, analysts expect that Femasys Inc. will post -0.84 EPS for the current fiscal year.

Institutional Trading of Femasys

Hedge funds and other institutional investors have recently modified their holdings of the stock. Aljian Capital Management LLC acquired a new stake in shares of Femasys during the third quarter valued at about $27,000. XTX Topco Ltd increased its position in Femasys by 123.9% in the 3rd quarter. XTX Topco Ltd now owns 32,535 shares of the company’s stock valued at $36,000 after acquiring an additional 18,004 shares during the period. Finally, Geode Capital Management LLC lifted its holdings in shares of Femasys by 9.2% during the third quarter. Geode Capital Management LLC now owns 206,483 shares of the company’s stock worth $229,000 after purchasing an additional 17,473 shares during the period. Institutional investors own 65.27% of the company’s stock.

About Femasys

Femasys Inc, a biomedical company, develops therapeutic and diagnostic solutions to address unmet women healthcare needs worldwide. The company provides FemVue saline-air device, a contrast-generating product in the United States, Canada, Japan, and Hong Kong; FemCath, a cornual balloon catheter, a single intrauterine directional delivery product that allows for selective evaluation of an individual fallopian tube; and FemCerv, a biopsy device for endocervical curettage, which can be used to sample cervical cells and tissue circumferentially with sample containment within the device to minimize contamination.